From an analysis of data viewed retrospectively on the outcomes of 68 patients with OM-CRPC, defined as five or fewer progressing lesions, treated with stereotactic ablative radiotherapy (SABR), Deek et al. reported that the time to PSA recurrence, TTNI, and median distant metastasis-free survival (DMFS) after PSDT were 9.7, 15.6, and 10.8 months, respectively [14]. This evidence concerns the gene KLK3 and ocular melanoma.